Sequence-dependent cytotoxicity of etoposide and paclitaxel in human breast and lung cancer cell lines

Cancer Chemotherapy and Pharmacology

Volumn 41, Issue 6, 1998, Pages 448-452

  Perez, Edith A ^a   Buckwalter, Christopher A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Breast; Cell culture; Etoposide; Lung; Paclitaxel

Indexed keywords

ETOPOSIDE; PACLITAXEL;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL STRAIN MCF 7; CLONOGENIC ASSAY; COMPUTER PROGRAM; CONTROLLED STUDY; CYTOTOXICITY; DOSE TIME EFFECT RELATION; DRUG POTENTIATION; HUMAN; HUMAN CELL; LUNG CANCER; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; ETOPOSIDE; FEMALE; HUMANS; LUNG NEOPLASMS; PACLITAXEL; TUMOR CELLS, CULTURED;

EID: 0031887272     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050765     Document Type: Article

References (14)

1. Brown T, Havlin K, Weiss G, Cagnola J, Koeller J, Kuhn J, Rizzo J, Craig J, Phillips J, Von Hoff D (1991) A phase I trial of taxol given by a 6-hour intravenous infusion. J Clin Oncol 9: 1261
2. Chou T-C (1991) The median-effect principle and the combination index for quantitation of synergism and antagonism. In: Chou T-C, Rideout DC (eds) Synergism and antagonism in chemotherapy. Academic Press, San Diego, p 61
3. Chou T-C, Talalay P (1987) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27
4. Chou TC, Otter GM, Sirotnak FM (1996) Schedule-dependent synergism of taxol or taxotere with edatrexate against human breast cancer cells in vitro. Cancer Chemother Pharmacol 37: 222
5. Dombernowsky P, Nissen NI (1973) Schedule dependency of the antileukemic activity of the podophyllotoxin-derivative VP 16-213 (NSC-141540) in L1210 leukemia. Acta Pathol Microbiol Scand A 81: 715
6. Donehower RC, Rowinsky EK, Grochow LB, Longnecker SM, Ettinger DS (1987) Phase I trial of taxol in patients with advanced cancer. Cancer Treat Rep 71: 1171
7. Ettinger DS, Finkelstein DM, Sarma RP, Johnson DH (1995) Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 13: 1430
8. Guchelaar HJ, ten Napel CH, de Vries EG, Mulder NH (1994) Clinical, toxicological and pharmaceutical aspects of the antineoplastic drug taxol: a review. Clin Oncol (R Coll Radiol) 6: 40
9. Hahn SM, Liebmann JE, Cook J, Fisher J, Goldspiel B, Venzon D, Mitchell JB, Kaufman D (1993) Taxol in combination with doxorubicin or etoposide. Possible antagonism in vitro. Cancer 72: 2705
10. Long BH (1987) Structure-activity relationships of podophyllin congeners that inhibit topoisomerase II. NCI Monogr 4: 123
11. Long BH, Musial ST, Brattain MG (1984) Comparison of cytotoxicity and DNA breakage activity of congeners of podophyllotoxin including VP16-213 and VM26: a quantitative structure-activity relationship. Biochemistry 23: 1183
12. Parness J, Horwitz SB (1981) Taxol binds to polymerized tubulin in vitro. J Cell Biol 91: 479
13. Rowinsky EK, Cazenave LA, Donehower RC (1990) Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 82: 1247
14. Schiff PB, Fant J, Horwitz SB (1979) Promotion of microtubule assembly in vitro by taxol. Nature 277: 665